New Amsterdam Pharma
Sheng Cui has worked in the pharmaceutical industry since 2006. Sheng began their career at Amgen, where they held the roles of Scientist, Senior Scientist, Principal Scientist, and Scientific Director. In 2019, they joined Boston Pharmaceuticals as Vice President, CMC, and later Executive Director, CMC. In 2021, they began working at NewAmsterdam Pharma as Executive Vice President, Head of CMC, and later Vice President, Head of CMC.
Sheng Cui received a Bachelor's degree in Chemistry from Nankai University. Sheng then went on to pursue a PhD in Chemistry from Case Western Reserve University, which they completed in 2003. Following this, they were a Postdoctoral fellow in Organic Chemistry at Harvard University from 2003 to 2006.
This person is not in any offices
New Amsterdam Pharma
1 followers
Founded in 2019 by the venture capital firm Forbion and John Kastelein, NewAmsterdam Pharma is a privately held, clinical-stage company focused on the research and development of transformative therapies for cardiometabolic diseases. Its mission is to improve patient care in populations where traditional therapies are not tolerated or have been unsuccessful.